Aura Biosciences Files 8-K with Corporate Updates
Ticker: AURA · Form: 8-K · Filed: 2024-06-21T00:00:00.000Z
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Aura Biosciences filed an 8-K on June 20th detailing corporate changes and upcoming shareholder votes.
AI Summary
Aura Biosciences, Inc. filed an 8-K on June 21, 2024, reporting events that occurred on June 20, 2024. The filing indicates changes to the company's articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 80 Guest Street, Boston, MA.
Why It Matters
This 8-K filing signals important corporate actions and potential upcoming votes by security holders, which could impact the company's governance and financial reporting.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information about significant financial distress or operational failures.
Key Players & Entities
- Aura Biosciences, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of earliest event reported
- June 21, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 80 Guest Street, Boston, Massachusetts 02135 (address) — Principal Executive Offices
FAQ
What specific amendments were made to Aura Biosciences' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in this summary section of the 8-K.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.
When did the events reported in this 8-K filing occur?
The earliest event reported occurred on June 20, 2024.
Where are Aura Biosciences' principal executive offices located?
Aura Biosciences' principal executive offices are located at 80 Guest Street, Boston, Massachusetts 02135.
What is Aura Biosciences' fiscal year end?
Aura Biosciences' fiscal year ends on December 31st.
Filing Stats: 947 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-06-21 16:07:00
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share AURA The Nasdaq
Filing Documents
- d783830d8k.htm (8-K) — 36KB
- d783830dex31.htm (EX-3.1) — 7KB
- 0001193125-24-165656.txt ( ) — 170KB
- aura-20240620.xsd (EX-101.SCH) — 3KB
- aura-20240620_lab.xml (EX-101.LAB) — 18KB
- aura-20240620_pre.xml (EX-101.PRE) — 11KB
- d783830d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Tenth Amended and Restated Certificate of Incorporation of the Registrant. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: June 21, 2024 By: /s/ Julie Feder Julie Feder Chief Financial Officer